Lack of p21(waf1) and p27(kip1) protein induction by interferon-α2a in human melanoma cell lines

Melanoma Research

Volumn 9, Issue 5, 1999, Pages 457-463

  Bearzatto, A ^a   Orlandi, L ^a   De Marco, C ^a   Daidone, M G ^a   Zaffaroni, N ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cell growth; Cyclin dependent kinases; Interferon 2a; STAT proteins

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA2A INTERFERON; CYCLIN DEPENDENT KINASE INHIBITOR; INTERFERON RECEPTOR; PROTEIN P21; PROTEIN P27; STAT1 PROTEIN; STAT2 PROTEIN; ALPHA BETA INTERFERON RECEPTOR; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; DNA BINDING PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; STAT1 PROTEIN, HUMAN; STAT2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; CELL NUCLEUS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; MELANOMA; METABOLISM; PATHOLOGY; TIME; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL DIVISION; CELL NUCLEUS; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; INTERFERON ALFA-2A; MELANOMA; MICROTUBULE-ASSOCIATED PROTEINS; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; TIME FACTORS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0032586031     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199910000-00005     Document Type: Article

References (24)

1. Platanias I.C. Interferons: laboratory to clinic investigations. Curr Opin Oncol 1995; 7: 560-565.
2. Leaman DW, Leung S, Li X, Stark GR. Regulation of STAT-dependent pathways by growth and cytokines. FASEB J 1996; 10: 1578-1288.
3. cip1 mediated by STAT1. Science 1996; 272: 719-722.
4. Sangfelt O, Erickson S, Einhorn S, Grander D. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines. Oncogene 1997; 14: 415-423.
5. kipl in a human gastric carcinoma cell line. Celt Growth Diff 1997; 8: 47-52.
6. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-582.
7. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
8. Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant Interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997; 15: 2351-2358.
9. Anichini A, Mazzocchi A, Fossati G, Parmiani G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J Immunol 1989; 142: 3692-3701.
10. Bae I, Smith ML, Sheikh MS, Zhan Q, Scudiero DA, Friend SH, O'Connor PM, Fornace AJ. An abnormality in the p53 pathway following γ-irradiation in many wild-type p53 human melanoma lines. Cancer Res 1996; 56: 840-847.
11. Supino R, Caserini C, Orlandi L, Zaffaroni N, Silvestrini R, Vaglini M, Zunino F. Modulation of melphalan cytotoxic activity in human melanoma cell lines. Anticancer Drugs 1996; 7: 604-612.
12. Schaber B, Mayer P, Schreiner T, Rassner G, Fierbeck G. Anti-proliferative activity of natural interferon-alpha, isotretinoin and their combination varies in different human melanoma cell lines. Melanoma Res 1994; 4: 321-326.
13. Bearzatto A, Orlandi L, Silvestrini R, Belli F, Cascinelli N, Zaffaroni N. Combined effects of interferon-α2a and 13-cis-retinoic acid on human melanoma cell growth and STAT protein expression. Melanoma Res 1998; 8: 31-38.
14. Novick D, Cohen B, Rubinstein M. The human interferon α/β receptor: characterization and molecular cloning. Cell 1994; 77: 391-400.
15. Abramovich C, Chebath J. Revel M. The human interferon α-receptor protein confers differential responses to human interferon-β versus interferon-α subtypes in mouse and hamster cell transfectants. Cytokine 1994; 6: 412-424.
16. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
17. Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ. Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression. J Clin Invest 1997; 99: 447-456.
18. 1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
19. Vidal MJ. Loganzo F Jr, de Oliveira AR, Hayward NK, Albino AP. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res 1995; 5: 243-250.
20. INK4d and cyclin D2 expression. J Biol Chem 1998; 273: 11799-11805.
21. Oya M, Konno S, Chen Y, Tazaki H, Mallouh C, Wu JM. Control of cell cycle regulatory proteins and modulation of STAT1 proteins by IFN-γ in human prostatic JCA-1 cells. Int J Oncol 1997; 10: 835-839.
22. waf1/cip1 protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997; 14: 929-935.
23. Yamada H, Ochi K, Nakada S, Takahara S, Nemoto T, Sekikawa T, Horiguchi-Yamada J. Interferon modulates the messenger RNA of G1-controlling genes to suppress the G1-to-S transition in Daudi cells. Mol Cell Biochem 1995; 152: 149-158.
24. Cip1 in mouse macrophages. Oncogene 1998; 16: 2075-2086.